These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 2488328)

  • 1. Lymphokine-activated killer lymphocytes: LAK and interleukin-2 in the treatment of malignancies of the central nervous system.
    Blacklock JB; Grimm EA
    Immunol Ser; 1989; 48():93-9. PubMed ID: 2488328
    [No Abstract]   [Full Text] [Related]  

  • 2. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.
    Tzeng JJ; Barth RF; Clendenon NR; Gordon WA
    Cancer Res; 1990 Jul; 50(14):4338-43. PubMed ID: 2364388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant adoptive immunotherapy for pediatric recurrent brain tumors.
    Lillehei KO; Johnson SD; McCleary EL; Mitchell DH; Schiltz PM; Kruse CA
    Online J Curr Clin Trials; 1993 Dec; Doc No 111():[806 words; 5 paragraphs]. PubMed ID: 8305997
    [No Abstract]   [Full Text] [Related]  

  • 4. [A history and prospect of adoptive immunotherapy against malignant glioma--past, now and future].
    Nitta T
    No To Shinkei; 1992 Jul; 44(7):605-13. PubMed ID: 1419336
    [No Abstract]   [Full Text] [Related]  

  • 5. The cellular immunotherapy of primary brain tumors.
    Hayes RL
    Rev Neurol (Paris); 1992; 148(6-7):454-66. PubMed ID: 1448666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Observations on the local administration of autologous lymphokine activated killer cells and recombinant interleukin-2 in patients with malignant gliomas].
    Yoshida S; Takai N; Ono K; Saito T; Tanaka R
    No To Shinkei; 1988 Feb; 40(2):119-25. PubMed ID: 3259433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Experimental studies on the antitumor activity of glioma-infiltrating lymphocytes against autologous glioma].
    Li Y
    Zhonghua Yi Xue Za Zhi; 1992 May; 72(5):284-6, 319. PubMed ID: 1327462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cellular immunotherapy for malignant glioma].
    Okamoto Y; Yamashita J
    Nihon Rinsho; 2005 Sep; 63 Suppl 9():557-62. PubMed ID: 16201581
    [No Abstract]   [Full Text] [Related]  

  • 9. Lymphokine-activated killer lymphocytes: biotherapeutics clinical trials.
    West WH
    Immunol Ser; 1989; 48():79-92. PubMed ID: 2488327
    [No Abstract]   [Full Text] [Related]  

  • 10. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
    Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T
    Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphokine-activated killer lymphocytes: extramural clinical trials.
    Sniecinski IJ
    Immunol Ser; 1989; 48():59-77. PubMed ID: 2488326
    [No Abstract]   [Full Text] [Related]  

  • 12. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial.
    Jacobs SK; Wilson DJ; Kornblith PL; Grimm EA
    Cancer Res; 1986 Apr; 46(4 Pt 2):2101-4. PubMed ID: 3512079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy with stimulated autologous lymphocytes in a case of a juvenile anaplastic glioma.
    Thomas C; Schober R; Lenard HG; Lumenta CB; Jacques DB; Wechsler W
    Neuropediatrics; 1992 Jun; 23(3):123-5. PubMed ID: 1641079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy with interleukin-2 and tumor-derived activated lymphocytes.
    Oldham RK
    Immunol Ser; 1994; 61():251-71. PubMed ID: 8011748
    [No Abstract]   [Full Text] [Related]  

  • 15. Lymphokine-activated killer lymphocytes: National Cancer Institute clinical trials.
    Clark J; Longo DL
    Immunol Ser; 1989; 48():37-58. PubMed ID: 2488325
    [No Abstract]   [Full Text] [Related]  

  • 16. Adoptive immunotherapy with adherent lymphokine-activated killer (A-LAK) cells in glioblastoma multiforme.
    Munari L; Silvani A; Passerini CG; Radrizzani M; Parmiani G; Boiardi A
    J Neurosurg Sci; 1990; 34(3-4):283-8. PubMed ID: 1965907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors.
    Sankhla SK; Nadkarni JS; Bhagwati SN
    J Neurooncol; 1996 Feb; 27(2):133-40. PubMed ID: 8699235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interleukin-2 and adoptive immunotherapy: their biological aspects and clinical application in oncology].
    Barón Saura JM; Pizarro Redondo A; Berrocal Jaime A; González Barón M
    Rev Clin Esp; 1991 May; 188(9):468-72. PubMed ID: 1896596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunotherapy of malignant melanoma].
    Flageul B; Miclea JM; Bensussan A; Degos L
    Pathol Biol (Paris); 1990 Oct; 38(8):881-2. PubMed ID: 2274397
    [No Abstract]   [Full Text] [Related]  

  • 20. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.